65,437 trials
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Post-traumatic Stress Disorder
Primary: Weekly Number of Nightmares — 3.95; 3.88; 3.28; 3.47 weekly nightmares
Myopia
Primary: Visual Acuity (VA) — -0.033; -0.038 LogMAR
Visual Impairment · Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Average BCVA Change From Month 1 Through Month 6 to Baseline — 14.6; 4.8 Letters
Diabetes
Primary: Number of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15 mg/dL (<100 mg/dL) and Within +/- 15% (>=100 mg/dL) of Laboratory Glucose Method — 127 Blood…
Psoriasis
Primary: Percent of Patients Achieving PASI 75 at 6 Months After the Addition of Acitretin Therapy — 12.5 percent
Acute, Uncomplicated Human Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 106.9; 91.1 hours — p=0.222
Chronic Plaque-type Psoriasis
Primary: Percentage of Participants of Reponders of Psoriasis Area and Severity Index (PASI) 75 Achievement at Week 13 — 3.4; 19.2; 57.1; 81.5 percentage of participants
Borderline Personality Disorder
Primary: Drop-out — 13; 20 participants
Pain · Sickle Cell Disease
Primary: Acute Chest Syndrome — 2; 1 participants
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Nicotine Dependence
Primary: Smoking Abstinence — 13; 24 participants
Anemia · Pregnancy Complications
Primary: Serum Ferritin Level — 136.1; 28.3 µg/dL
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Documented CR, CRi, or PR at the End of Induction Treatment — 82.4 percentage of participants — p=0.0008